What do systematic reviews say?

Alglucosidase alfa plus albuterol vs alglucosidase alfa plus placebo

• Enzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 5 participants
  Very low

Alglucosidase alfa plus albuterol vs alglucosidase alfa plus placebo

• Enzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 5 participants
  Very low

Alglucosidase alfa plus albuterol vs alglucosidase alfa plus placebo

The review found no eligible studies for this question.

• Enzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Alglucosidase alfa plus albuterol vs alglucosidase alfa plus placebo

The review found no eligible studies for this question.

• Enzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Alglucosidase alfa plus albuterol vs alglucosidase alfa plus placebo

The review found no eligible studies for this question.

• Enzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Alglucosidase alfa plus albuterol vs alglucosidase alfa plus placebo

The review found no eligible studies for this question.

• Enzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Alglucosidase alfa plus albuterol vs alglucosidase alfa plus placebo

It is very uncertain whether alglucosidase alfa plus albuterol changes adverse events compared with alglucosidase alfa plus placebo (very low certainty).

• Enzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes only
  RR 0.67 [0.38, 1.18]
  1 study · 13 participants
  Very low